|
|
 |
|
Viewing report
|
|
|
|
R&D Trends: Attention-Deficit Hyperactivity Disorder - Growing pipeline indicates a trend towards adjunctive and adult therapy
Datamonitor, June 2011, Pages: 69
Introduction
Two drugs have progressed through the pipeline representing the first two products to receive US FDA approval for use as adjunctive therapies to stimulants: Intuniv (extended release guanfacine; Shire) and Kapvay (clonidine; Shionogi). Interest in the ADHD pipeline remains high as companies continue to attempt to demonstrate differentiation in the increasingly competitive market.
Features and benefits
- Understand key R&D dynamics in the pipeline for new ADHD therapies.
- Benchmark novel and existing therapies using the target product profile identified by Datamonitor.
- Support R&D decision making by evaluating clinical trial designs that have set a precedent.
- Evaluate the most promising new pharmacological targets in early-stage development.
- Access The prediction of how the treatment landscape may change in the next 20 years.
Highlights
The ADHD drug pipeline has almost doubled since 2008 with 25 candidates in clinical development. Although large and medium sized Pharma are present, the pipeline is dominated by smaller companies that will need licensing partners to bring their products to market.
Trends in the ADHD drug pipeline indicate a growing interest in non-stimulant agents used as add-on therapies to stimulants, with around a quarter of non-stimulants under investigation for adjunctive use. Datamonitor sees this is as a viable market entry point amid high competition.
Increasingly, companies view the adult ADHD population as a more viable target than pediatric ADHD due there being less competition, increasing disease awareness, and fewer challenges in conducting clinical trials.
Your key questions answered
- What are the key trends in the ADHD pipeline?
- What key companies are involved in the pipeline? What encourages and deters companies from investing in this area?
- What is the clinical gold standard and how do new candidates have to compare to this to successfully penetrate the market?
- How is the treatment of ADHD likely to evolve over the next 10 to 20 years?
|
|
|
|
